Curated News
By: NewsRamp Editorial Staff
September 03, 2025
Sigyn Therapy Study Targets Cardiovascular Death Reduction in Dialysis Patients
TLDR
- Sigyn Therapeutics' blood purification technology offers a competitive edge by potentially extending ESRD patient lives and increasing dialysis industry revenues by billions.
- Sigyn Therapy uses whole-blood adsorption on dialysis machines to reduce inflammatory molecules and cholesterol lipoproteins that drive cardiovascular disease progression.
- This technology could significantly reduce global cardiovascular deaths and improve quality of life for high-risk patients worldwide.
- Sigyn Therapy simultaneously targets multiple cardiovascular risk factors during routine dialysis, making treatment more accessible and convenient for patients.
Impact - Why it Matters
This development matters because cardiovascular disease remains the leading cause of death globally and is particularly devastating for end-stage renal disease patients undergoing dialysis. Current lipoprotein apheresis treatments, while effective, are severely limited to specialized centers, leaving most patients without access. Sigyn Therapy's potential to be deployed on existing dialysis equipment could democratize life-extending treatment for hundreds of thousands of high-risk patients while addressing the $34 billion dialysis industry's fundamental challenge of cardiovascular mortality. Successful implementation could transform standard care protocols and significantly improve survival rates for one of medicine's most vulnerable patient populations.
Summary
Sigyn Therapeutics, Inc. (OTCQB: SIGY), a developer of next-generation blood purification technologies, has announced plans to commence a multi-site clinical feasibility study of its innovative Sigyn Therapy™ in high-risk cardiovascular disease patients. This groundbreaking approach targets the reduction of major adverse cardiovascular events (MACE) by simultaneously addressing inflammatory molecules and cholesterol-transporting lipoproteins that contribute to heart attacks and strokes. The study builds on pre-clinical insights and aims to quantify lipoprotein reduction, potentially setting the stage for pivotal efficacy studies and future market clearance.
Sigyn Therapy™ represents a first-in-class whole-blood adsorption technology designed for deployment on existing dialysis machines in approximately 7,500 U.S. dialysis clinics, dramatically expanding access compared to the fewer than 60 specialized apheresis centers currently available. This technology offers particular promise for end-stage renal disease (ESRD) patients, who face significantly elevated cardiovascular risks during dialysis treatments. CEO Jim Joyce emphasizes that targeting Lp(a) and LDL-C reduction while suppressing dialysis-induced inflammation introduces a broad-spectrum strategy to extend patient lives by addressing multiple core drivers of cardiovascular disease progression.
The potential impact extends beyond clinical benefits to substantial economic considerations, as the U.S. dialysis industry generates approximately $34 billion annually from over 85 million treatments administered to more than 550,000 ESRD patients. Extending patient lives by just one month could increase industry revenues by approximately $2.8 billion, primarily benefiting market leaders Fresenius Medical Care and Davita, Inc., who control 75% of the market. Readers can learn more about this developing story by visiting the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sigyn Therapy Study Targets Cardiovascular Death Reduction in Dialysis Patients
